Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Now the confidential doc I found few days ago and posted here makes sense. In case you missed it, here it is again. Search for Faron.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.icnarc.org/DataServices/Attachments/Download/00cb93c6-de7f-ea11-9124-00505601089b&ved=2ahUKEwi8yv36_fzoAhXLTcAKHWlkB-cQFjAJegQICRAB&usg=AOvVaw0Y_OBNfilpPEGF_lMfE3gw
I found an interesting doc for us "Faronians". Can't attach it but hope you can download it OK from the link below. Some more info for those who are interested in Remap-Cap study. Worth searching a word "Faron" (unless you wish to read it from cover to cover).
I topped up my position today. Hoping for the best...
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.icnarc.org/DataServices/Attachments/Download/00cb93c6-de7f-ea11-9124-00505601089b&ved=2ahUKEwi8yv36_fzoAhXLTcAKHWlkB-cQFjAJegQICRAB&usg=AOvVaw0Y_OBNfilpPEGF_lMfE3gw
Thank you for this! What an encouraging interview. Markku seemed a bit tired, possibly working flat out... It made me smile when he said: "I haven't lost my trust in Traumakine at all" and smiled quietly. I'm reading a bit into his body language but that can only mean good news! In general, Finns are very modest, when they say something is "not bad", or "good" it actually means excellent.
G'morning to all,
Just combing through Faron's Annual Report 2019. Noticed a small paragraph about a new use of AOC3 inhibitors (p.8). So tell me, you wise ones, could Faron have another product in making?
AOC3 ANTAGONIST PLATFORM TECHNOLOGY
• In March 2020, Faron acquired rights for the potential
new use of AOC3 inhibitors. Faron will be responsible
for the future development of the AOC3 protein
inhibitor and for the management, prosecution
maintenance and filing of patent applications.
Faron has published that on 2 March too.
https://otp.tools.investis.com/clients/uk/faron1/rns/regulatory-story.aspx?cid=2223&newsid=1375795
This is a very smart observation. I believe those machines are expensive, machines also require space and someone to look after the machines too. If anyone listens Investors Chronicle podcast, I'd recommend the latest one published on 19 March.
I believe in Clevegen, and there will be other viruses after covid-19. Traumakine will have its use, if not now, later.
On the other hand, I should be happy that company is utilities publicity when it can. In addition, Faron discovered swiftly why Traumakine trial didn't get the outcome Faron expected. My understanding is that the discovery why Traumakine failed, has already positively influenced WHO's recommendations how Corona patients should be treaded.
We are in the midst of the strange times. This is the loniest mother's day for many. I'm lucky enough to be healthy, and all my family are safe and well so far.
Faron puts it well on its website, "It's all about saving lives". More pertinent slogan than ever in my lifetime.
More publicity in Finland. Yle is like BBC in the UK.
Nothing new here, all has been said before. However, this article is potentially seen by many more eyes than those previous newspaper articles.
https://yle.fi/uutiset/3-11269601
Google translate can't cope with idioms, but it is OK translation otherwise.
https://translate.googleusercontent.com/translate_c?depth=1&hl=en&nv=1&rurl=translate.google.com&sl=fi&sp=nmt4&tl=en&u=https://yle.fi/uutiset/3-11269601&usg=ALkJrhitrHLWrqFxMmzpJyy7Jd876IsacQ
Faron Presentation summary (2/2)
Positives:Clevegen can be used to treat multiple different cancer types - > larger user base.
Covid-19 virus is no different from any other flu virus that causes similar symptoms that Traumakine can treat (successfully).
IF Faron has to comply fully to medical testing, it will be three (3) years before Traumakine can be brought to the commercial use. IF authorities see a situation where medicine's use is important enough for public safety, the authorities can make a case for allowing the drug to be used in patient care based on a compassionate use policy. In addition, an individual medic/doctor can apply for individual permission from medical authorities to use the drug to care for a patient. My understanding is that drug cannot be brought to the market any faster than three years, but its use can be permitted if authorities see it being beneficial for public safety.
Traumakine won't replace medicine used for people suffering from asthma.
Faron is an expert at running clinical research. A team of 25 people are conducting world-leading research in ARDS, the majority of that is done outside Finland. Faron has operated in the field for a long time and has established a good relationship with all the parties working on the field. Commercial partnerships have been established already (I've seen this published) but the company is still managing the commercial side of the business in Europe and the USA. Markku feels that they have succeeded exceptionally well in managing the relationships with all the researchers, commercial parties and conducting the first-class research in the field, especially in cancer and ARDS research. Nevertheless, it's a long process, outcomes are not instant.
Traditionally, cancer has been classified based on the organ its originates ie. liver cancer etc. Based on the latest research this all could change. This bit is related to Clever-1. This is the exciting bit "One ring to rule them all" as you can remember from Juha's earlier presentation this year.
This is all I can manage today. Hope the above is some help. I feel extremely positive esp. what comes to Clevegen. Do not be fooled having your hopes up with Corona and Traumakine. Public safety first. Medicine has to be properly tested.
Ok guys and girls. I have to split this message into two messages due to character limit. This is a follow up what I wrote yesterday.
Disclaimer. I'm in this for a charity. A novice investor who has taken a small financial risk. I have no medical training and no competence to analyse the company's product nor finances. My opinions are based on how I understood the presentation and what is my "feeling" is.
The last few days I have not even had any headspace really to devote to the share price. It goes up or down, no matter to me - I don't trade stocks and shares for a living.
However, I enjoyed listening to the Finnish presentation. I have also listened to the previous presentations available in English, all freely available via YouTube. There was nothing fundamentally different or new for anyone who has been following the company for the long term. The most interesting points came out at the end of the presentation when people were asking questions.
I cannot remember anymore what I wrote yesterday. There have been 200+ messages since my previous post so I won't even try to find it. I just want to note that I share the same sentiment the nickname LeiwoUnion had. Check his posts out as his opinion made a lot of sense to me. So I agree with him, based on the presentation, Markku was clear that Traumakine is in approx. 3 years in making. There is a chance it can be trialled based on the Compassionate Use policy with some patients. Traumakine must pass its trials and tests before it can be brought to the market fully. This will take time. It's not realistic to expect it is able to help the wider population now. Having said that, Covid-19 won't be the last virus that we will be facing and ARDS cases won't stop happening after Covid-19 is no longer our immediate worry *which I hope is asap*. I can see a good potential holding on to my shares.
My plan with Farn is to keep an eye on how it is going and if the price goes down to the level that I'm happy to buy, I will buy. But I will only put the money in that I can live without - forever.
Presentation followed the slides seen in the link belowhttps://www.faron.com/sites/default/files/Full%20year%202019%20result%20presentation%20200320.pdf
I have only had a chance to see the first half of the presentation so far. Markku explained why they went for dual listing. Reason being majority of Faron's investors are based in Finland and buying stock via LSE AIM is not that easy from Finland, apparently.
A fair bit of info about Clevegen. I had no idea how amazing potential that drug has. I started to feel I'm part of something amazing with my little investment.
What comes to Traumakine, I have not watched it all yet. Markku talked about Compassionate Use. Please google it up as I know nothing about medical trials.
I'll watch the rest now and hopefully can give you all a better summary tomorrow.
Stay safe, isolated if required and pass on only kindness.